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Since the start of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
pandemic, a disease that has become one of the world's greatest global health
challenges, the role of the immune system has been at the forefront of scientific
studies. The pathophysiology of coronavirus disease 2019 (COVID-19) is complex,
which is evident in those at higher risk for poor outcome. Multiple systems contrib-
ute to thrombosis and inflammation seen in COVID-19 patients, including neutrophil
and platelet activation, and endothelial dysfunction. Understanding how the immune
system functions in different patient cohorts (particularly given recent emerging
events with the Oxford/AstraZeneca vaccine) is vital to understanding the patho-
physiology of this devastating disease and for the subsequent development of novel
therapeutic targets and to facilitate possible drug repurposing strategies that could
benefit society on a global scale.
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1 | INTRODUCTION
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the
aetiological agent of coronavirus disease 2019 (COVID-19), a disease
that has had global impact, with case rates surging to over 3000
deaths a day across Europe alone. Moreover, since the initial reported
emergence in December 2019 in the Hubei Province of Wuhan,
China, and the World Health Organisation (WHO) declaring the
COVID-19 outbreak a pandemic (11 March 2020), 128 million
confirmed cases of COVID-19 have been reported globally, including
2.8 million deaths. As of this year (2021), there have been profound
breakthroughs such as the approval and administration of vaccines
from Pfizer-BioNTech, Moderna and Oxford/AstraZeneca, with
additional vaccines from Valneva, CureVac Novavax and Johnson &
Johnson currently under assessment by the Medicines and Healthcare
products Regulatory Agency (MHRA), with others in the pipeline
(e.g., GlaxoSmithKline/Sanofi Pasteur's vaccine, which may be
available by the final quarter of 2021).
Abbreviations: AnxA1, annexin A1; ARDS, acute respiratory distress syndrome; C3, complement component 3; C4d, complement component C4d; C5b-9, complement component C5b; CD8+ T
cell, cytotoxic T cell; CoV, coronavirus; COVID-19, coronavirus disease 2019; DAMPs, danger-associated molecular patterns; factor IIa, blood coagulation factor IIa; GP, glycoprotein; GPIb,
CD42, glycoprotein Ib; LMWH, low-molecular-weight heparin; Mac-1, CD11b/CD18, macrophage 1; MASP-2, mannose-binding lectin-associated serine protease-2; MBL, mannose-binding
lectin; MERS-CoV, Middle East respiratory syndrome coronavirus; MHRA, Medicines and Healthcare products Regulatory Agency; MPO-DNA, myeloperoxidase-DNA; NETs, neutrophil
extracellular traps; PNAs, platelet–neutrophil aggregates; PSGL-1, P-selectin glycoprotein ligand-1; RBD, receptor-binding domain; RCTs, randomised controlled trials; S, transmembrane spike;
SARS-CoV, severe acute respiratory syndrome coronavirus; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; TF, tissue factor; TMPRSS-2, transmembrane protease serine 2; UFH,
unfractionated heparin; WHO, World Health Organisation.
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1.1 | Coronaviruses
Coronaviruses (CoVs), of which there are four genera (alpha, beta,
gamma and delta), are a family of enveloped, positive-sense,
single-stranded and highly diverse RNA viruses (Zhu et al., 2020).
Three betacoronaviruses have been identified to cause severe
respiratory illness in humans including severe acute respiratory
syndrome CoV (SARS-CoV), Middle East respiratory syndrome CoV
(MERS-CoV) and SARS-CoV-2 (McFadyen et al., 2020). Although
bats have been suggested to be the primary origin of SARS-CoV
and SARS-CoV-2, the precise origin and mechanism by how
SARS-CoV-2 manifested in humans is still unclear, with other possi-
ble hosts (such as the Malayan pangolins [Manis javanica]), under
investigation (Lam et al., 2020).
SARS-CoV-2 is a single-stranded RNA virus, and entry into host
cells initiates with their transmembrane spike (S) glycoproteins (GPs)
encompassing S1 and S2 subunits. The S1 unit binds to host cell
receptors, whereas the S2 subunit aids in viral and host cell fusion
(Walls et al., 2020). Like SARS-CoV, SARS-CoV-2 binds via the human
ACE2, a cell surface protein with peptidase activity, expressed on the
endothelial surface (Davidson et al., 2020; Hoffmann et al., 2020). In
comparison with SARS-CoV, SARS-CoV-2 has different amino acid
residues within the receptor-binding domain (RBD) of the S protein
and a polybasic furin cleavage site at the junction of S1 and S2. In
addition, transmissibility and pathogenicity of SARS-CoV-2 is linked
to cellular proteases such as furin and the transmembrane protease
serine 2 (TMPRSS-2) (McFadyen et al., 2020). Although the function-
ality of these specific features of SARS-CoV-2 has yet to be fully elu-
cidated, they could provide key information to the prothrombotic
phenotype associated with SARS-CoV-2 and why patients with this
specific CoV have higher thrombosis rates than SARS-CoV and
MERS-CoV infections.
1.2 | Clinical manifestations and
thromboinflammation
A number of clinical manifestations such as fever, dry cough, malaise,
sore throat, chest pain, dyspnoea, nausea, diarrhoea and vomiting
have been associated with SARS-Cov-2 infection (Tian et al., 2020).
The spectrum of symptomatic infection ranges from mild to critical,
although there remains uncertainty around the proportion of asymp-
tomatic infections. Among hospitalised patients, the proportion of
critical or fatal disease is higher, with many progressing to acute respi-
ratory distress syndrome (ARDS), respiratory failure and eventually
death (Bost et al., 2021). Interestingly, the ARDS associated with
COVID-19 patients differs from that caused by other infective or
traumatic insults, with the ‘cytokine storm’ (i.e., increased cytokines
released from the blood, which is associated with disease severity)
being only partly involved in COVID-19 patients (Maier et al., 2020).
Furthermore, IL-6 levels are 60-fold to 90-fold higher in ARDS
patients compared with COVID-19 patients, although the reasons for
these differences are unknown. It is conceivable that SARS-CoV-2
takes over the host immune system, impairing antiviral immunity and
triggering chronic inflammation by involving inflammatory cytokines
(Bost et al., 2021; Sinha et al., 2020). Certainly, a hallmark of SARS-
CoV-2 is the release of not only IL-6 but also other cytokines and
chemokines including IL-1β, IL-2, IL-6, IL-7, IL-8, IL-10, IL-17, TNF-α,
CCL2, CCL3 and CXCL10, all of which correlate with adverse
clinical outcomes. The inflammatory effects of cytokines also activate
vascular endothelial cells, disrupting endothelial function and integrity,
which leads to increased platelet and leukocyte recruitment,
resulting in a pro-inflammatory and prothrombotic state (Connors &
Levy, 2020).
Autopsy reports from SARS-CoV-2 patients show multi-organ
dysfunction, with highest viral titres in the lungs and immune cells,
and the presence of endothelial inflammation and cell death
(Gu et al., 2005; Mazzulli et al., 2004). It is likely that hypoxia also pro-
motes a prothrombotic endothelial phenotype in SARS-CoV-2 via
hypoxia-inducible transcription factor activation and endothelial tis-
sue factor (TF) up-regulation.
The scale of COVID-19 severity also increases with co-
morbidities such as hypertension, chronic kidney disease, obstructive
sleep apnoea, asthma diabetes and obesity (Tian et al., 2020). Patients
with underlying cardiovascular disease are prone to increased severity
of COVID-19 and a fivefold increase in mortality (Yang et al., 2020).
Therefore, managing and controlling cardiovascular risk factors is a
high priority.
COVID-19 is associated with a prothrombotic state, which can
manifest as microvascular thrombosis, venous thromboembolism or
arterial thrombosis (McFadyen et al., 2020). The cause of this pro-
thrombotic state may relate to the appreciated link between thrombo-
sis and inflammation (termed ‘thromboinflammation’) in which
thrombosis can amplify inflammation and systemic inflammation can
beget thrombosis. Although efforts to understand the complex immu-
nological landscape in COVID-19 are evolving, both platelet activation
and platelet–neutrophil interactions play a crucial role in
thromboinflammation.
2 | ROLE OF NEUTROPHILS IN COVID-19
Neutrophils are the immune system's first responders having crucial
functions in immunity and repair. Upon activation, they produce
pro-inflammatory cytokines (including IL-6, TNF-α and IL-1β), gener-
ate ROS and release haematopoietic serine proteases (neutrophil
elastase, proteinase 3 and cathepsin G), microparticles and neutro-
phil extracellular traps (NETs). Neutrophils possess antimicrobial
properties capable of not only killing both Gram-positive and
Gram-negative bacteria, but they can also act as a double-edged
sword mediating tissue injury and perpetuating the inflammatory
response (Kolaczkowska & Kubes, 2013). NETs, ROS and serine
proteases can all independently, or collectively, up-regulate
thromboinflammatory processes.
In the context of COVID-19, neutrophilia signifies worse out-
comes, with autopsy studies showing neutrophil infiltration in
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pulmonary capillaries, acute capillaries with fibrin deposition, extrava-
sation of neutrophils in the alveolar space and neutrophil mucositis of
the trachea (Gu et al., 2005; Yao et al., 2020). Bost et al. (2021) rev-
ealed at least 10 different neutrophil states present in blood and
bronchoalveolar lavage of COVID-19 patients, with resting state phe-
notype mainly associated with patients with mild disease, and acti-
vated or immature phenotype associated with patients with severe
disease. These results suggest that COVID-19 is associated with a
state of ‘immune silence’ (demonstrated by loss of neutrophil and
monocyte immunosuppression and the replacement of lung memory
CD8+ T cells by naïve T cells), correlating with severe clinical manifes-
tation and outcome (Bost et al., 2021). Diao et al. (2020) showed that
T cells are dysfunctional with increased expression of exhaustion
molecules related to heightened systemic inflammation, including IL-6
levels. We have previously shown that IL-6 plays a major role in
T cell-dependent thromboinflammatory responses to angiotensin II
and in the activation and aggregation of platelets (Senchenkova,
Russell, et al., 2019). These findings support the hypothesis that drug
discovery programmes based on T cell-dependent, IL-6 signalling
pathways may lead to protection against thromboinflammation in
COVID-19 (Figure 1).
As observed with other pathological conditions (e.g., sickle
cell disease) (Ansari et al., 2021), NET levels are increased in
COVID-19 patients, with sera from COVID-19 patients being
shown to trigger NET release from control neutrophils and
containing increased myeloperoxidase-DNA (MPO-DNA) complexes
and citrullinated histone H3 levels, which correlated with disease
severity (Veras et al., 2020; Zuo et al., 2020). These results suggest
that NETs may contribute to COVID-19 pathology and NET
biomarkers may help to predict clinical worsening and venous
thromboembolism.
Neutrophil degranulation and NET formation lead to various
intracellular danger-associated molecular patterns (DAMPs)
activating pattern recognition receptors on nearby immune and
non-immune cells releasing pro-inflammatory mediators (Tomar
et al., 2020). DAMPs activate properdin, factor B and C3, all
components of the alternative pathway necessary to induce the
complement cascade. Reports have shown increased activation of
the complement system in severe COVID-19 patients (Holter
et al., 2020). Lung biopsies from COVID-19 patients have shown
deposits of terminal complement components C5b-9, C4d and
mannose-binding lectin (MBL)-associated serine protease-2
(MASP-2), consistent with sustained, systemic activation of the
complement pathways (Magro et al., 2020). These findings highlight
the therapeutic strategy of complement targeted therapies for
COVID-19-mediated thrombosis.
F IGURE 1 Thromboinflammation in coronavirus disease 2019 (COVID-19). (1) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
binds via the ACE2 expressed on the endothelial surface. The virus activates monocytes releasing a cytokine storm (including IL-6, IL-1β, IL-2, IL-6,
IL-7, IL-8, IL-10, IL-17, TNF-α, CCL2, CCL3, and CXCL10, all of which correlate with adverse clinical outcomes). (2) The inflammatory effects
of cytokines also activate vascular endothelial cells (ECs), disrupting endothelial function and integrity, which leads to increased platelet and
neutrophil recruitment. (3) Increased neutrophil at inflammatory site results in increased expression of adhesion molecules such as L-selectin,
P-selectin and intercellular adhesion molecule-1 on ECs. Activated neutrophils release their neutrophil extracellular traps (NETs, which contain a
backbone of DNA and citrullinated histone [H3Cit], cathepsin G and neutrophil elastase [NE]), which trap platelets, increasing their activation and
aggregation; this in turn further activates neutrophils to produce more NETs. (4) This cycle of events triggers coagulation cascade activation, which
in turn increases fibrin formation and thrombosis. CAMs, cellular adhesion molecules; RBC, red blood cell; vWF, von Willebrand factor
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The initial neutrophil response also leads to interactions with
platelets via a variety of different mechanisms including Mac-1
(CD11b/CD18)/glycoprotein Ib (CD42) and P-selectin/P-selectin
glycoprotein ligand-1 (PSGL-1), formation of fibrin cross-links
(via Mac-1/fibrin interaction) and induction of extrinsic TF/factor IIa
pathway, generating thrombin (De Meyer et al., 2016). TF-enriched
NETs and a high neutrophil count are associated with increased dis-
ease severity and poor prognosis in COVID-19 (Skendros et al., 2020),
amplifying the need for increased research regarding platelet–
neutrophil interactions in thrombogenesis.
3 | ROLE OF PLATELETS IN COVID-19
Platelets are traditionally known for their role in haemostasis and for-
mation of thrombi. However, they are increasingly being recognised
as key effector cells in inflammation, influencing innate and adaptive
immune responses (Senchenkova, Ansari, et al., 2019). Migration of
single platelets acts as mechanosensors to collect and bundle bacteria
for neutrophil phagocytosis (Gaertner et al., 2017), although their
uncontrolled activation can result in pathogenic thrombosis. Platelets
from COVID-19 patients show increased aggregation, adhesion and
spreading on fibrinogen and collagen (via up-regulation of the MAPK
pathway) and increased activity of thromboxane A2 (marker of plate-
let activation) (Manne et al., 2020).
Thrombocytopenia in COVID-19 is common, with meta-analysis
demonstrating a link with a fivefold increased risk of severe disease
(Lippi et al., 2020). Thrombocytopenia has also been linked with issues
of rare blood clotting events, which are now associated with the
Oxford/AstraZeneca vaccine (ongoing pharmacovigilance will
determine outcome), with seven deaths being reported in the 30 cases
reported in the United Kingdom alone (at the time of writing this
review, evidence is shifting towards a causal link between the vaccine
and rare blood clots).
Elevated D-dimers, fibrinogen and von Willebrand factor levels
are also associated with a higher mortality rate. Autopsies of cardiac
and pulmonary tissue from COVID-19 patients have shown the pres-
ence of megakaryocytes (Rapkiewicz et al., 2020). A recent study by
Manne et al., using platelet RNA sequencing, demonstrated COVID-
19-induced significant changes in platelet transcriptome and prote-
ome, and platelet hyperreactivity (Manne et al., 2020), which may
contribute to COVID-19 pathophysiology by increasing platelet
homotypic and heterotypic interactions. During infection, platelets
became hyperactive as shown by the increased surface P-selectin
expression and increased formation of circulating platelet–neutrophil
aggregates (PNAs) via binding with PSGL-1 (Manne et al., 2020). The
generation of PNAs recruit neutrophils to damaged lung capillaries.
Thrombotic events in COVID-19 may be attributed to platelets
augmenting inflammation through the generation of NETs and pro-
coagulant platelets, increased aggregates (e.g., PNAs) and the release
of bioactive substances. A greater understanding of the role that neu-
trophils and platelets play in thromboinflammation and their
involvement in the pathophysiology of COVID-19 is needed for drug
discovery focusing on dampening thromboinflammatory processes.
4 | THERAPEUTIC INTERVENTION
THROMBOINFLAMMATION RESOLUTION
Understanding neutrophil and platelet responses in the context of
thromboinflammation in COVID-19 has resulted in promising preclini-
cal studies demonstrating that, for example, immune regulatory prop-
erties are being lost in patients with COVID-19, with the virus
seemingly to ‘suppress’ or ‘silence’ the immune system (Bost
et al., 2021). Drugs that can ‘stimulate’ or ‘reawaken’ the immune
system may be the way forward, as seen with dexamethasone (Bost
et al., 2021; The RECOVERY Collaborative Group et al., 2021). Other
therapies may lie in targeting the cytokine storm with anti-
inflammatory agents such as IL-6 and IL-1β antagonists.
Accumulating data linking inflammation and thrombosis sup-
ports the hypothesis that anti-inflammatory therapies may limit
thrombosis and that antithrombotic therapies may reduce vascular
inflammation (Vital et al., 2016). Due to the high incidence of
thrombotic events seen in severe stages of COVID-19, most clinical
guidelines agree to the administration of low-molecular-weight hep-
arin (LMWH), as thrombo-prophylaxis, to hospitalised COVID-19
patients. However, the correct dose for hospitalised patients and
thromboprophylaxis approach to ambulant patients remains contro-
versial. A wide range of antithrombotic therapies are currently
being assessed in ongoing and recent randomised controlled trials
(RCTs) directed at outpatients, hospitalised patients and critically ill
patients with COVID-19. These trials involve the use of antiplatelet
agents, anticoagulants and fibrinolytic agents or a combination
(Table 1). Current antithrombotic therapies and interventions for
COVID-19 include: thromboprophylaxis with unfractionated
heparin (UFH), or LMWH; an intensive thromboprophylaxis protocol
with LMWH, antithrombin, clopidogrel and salvage therapy
with tissue plasminogen activator and heparin (Maldonado
et al., 2020).
There is a growing evidence of the importance of resolution biol-
ogy in vascular inflammation to develop innovative approaches for
the treatment of diseases, which may include COVID-19. Inflamma-
tion resolution is an active process involving specific endogenous
mediators (e.g., annexin A1 [AnxA1] and aspirin-triggered lipoxin A4)
and pathways (e.g., formyl peptide receptor 2 [FPR2/ALX] pathway)
(Senchenkova, Ansari, et al., 2019). FPR2 agonists are being devel-
oped and currently tested in man. In the context of throm-
obinflammation and the possible insights for therapeutic strategies for
COVID-19 treatments, we recently discovered that targeting the
AnxA1/Fpr2/ALX pathway promotes thromboinflammation resolution
by altering both the platelet phenotype (from pro-pathogenic to
regulatory) (Senchenkova, Ansari, et al., 2019) and the pathological
neutrophil phenotype (from a pro-NETotic to pro-apoptotic)
(Ansari et al., 2021).
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REMAP-CAP Aspirin or P2Y12 receptor
antagonists
NCT02735707 7100 patients to receive multiple therapeutic
interventions; anticoagulant arm and antiplatelet
agent arm evaluating aspirin and P2Y12 receptor
antagonists clopidogrel, ticagrelor or prasugrel.
PEAC Aspirin NCT04365309 Aims to test efficacy of aspirin in shortening clinical
recovery time.
RECOVERY Aspirin — Investigation of the effects of aspirin on all-cause
mortality among hospitalised patients with 20,000
participants.
RESIST Aspirin and atorvastatin CTRI/2020/07/026791 Evaluation of the role of aspirin and atorvastatin in
clinical deterioration by progression in accordance
with the WHO clinical improvement ordinal score in
800 hospitalised patients.
CAM-COVID-19 Aspirin — Evaluating the impact of a higher dose of aspirin in 34
patients (325 mg four times a day) in addition to
colchicine and montelukast on inflammatory markers
such as high-sensitivity C-reactive protein.
PARTISAN Prasugrel NCT04445623 Comparing the effect of prasugrel with placebo among
128 patients on the primary outcome of improved
oxygen expressed as the PaO2/FiO2 ratio at 7-day
follow-up.
Antithrombotic drugs
DAWn-Antico LMWH or UFH — A randomised, open-label, adaptive, proof-of-concept
clinical trial of modulation of host
thromboinflammatory response in patients with
COVID-19. Comparison of low MW heparins at
50-IU anti-Xa per kg twice daily—or 75-IU anti-Xa
twice daily for ICU patients—in combination with
aprotinin to standard thromboprophylaxis in
hospitalised COVID-19 patients.
X-COVID-19 LMWH or UFH — —
COVID-19 HD LMWH or UFH — RCT comparing efficacy and safety of high vs. low
LMWH dosages in hospitalised patients with severe
COVID-19 pneumonia and coagulopathy not
requiring invasive mechanical ventilation.
COVI-DOSE LMWH or UFH — Weight-adjusted vs. fixed low doses of LMWH for
venous thromboembolism prevention in COVID-19.
EMOS-COVID LMWH or UFH NCT04360824 Testing efficacy and safety of prophylactic
anticoagulation therapy in hospitalised patients.
Direct oral anticoagulants (DOACs)
ACTION Rivaroxaban NCT04394377 RCT to evaluate a routine full anticoagulation strategy
in patients with coronavirus compared with usual
SOC with prophylactic anticoagulation involving
20-mgday1 rivaroxaban followed by enoxaparin/
UFH vs. control group with 40-mgday1
enoxaparin.
COVID-PREVENT Rivaroxaban — A study investigating the effect of anticoagulation
therapy on clinical outcomes in COVID-19.
FREEDOM Edoxaban NCT04512079 A multicentre, open-label RCT determining
effectiveness and safety of enoxaparin and apixaban
in patients hospitalised (but not yet intubated) with
COVID-19.
XACT Rivaroxaban NCT04640181 A multicentre RCT studying the potential benefit of
treatments with a direct Factor Xa inhibitor
(Continues)
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5 | CONCLUSION
COVID-19 is a devastating disease that has affected the United
Kingdom and our global community in unprecedented ways. The
pathophysiology is complex with many systems likely to contribute to
the prothrombotic state including inflammation, platelet and neutrophil
activation, endothelial cell dysfunction, NETs and complement
factors. However, the mechanism that drives COVID-19-associated
thromboinflammation has not yet been fully elucidated and there is
an urgent unmet clinical need to fully understand and characterise
this disease. These discoveries will unearth ways to develop pharmaco-
logical strategies, which may also focus on resolution biology.
5.1 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in the IUPHAR/BPS Guide to PHARMACOLOGY
(http://www.guidetopharmacology.org) and are permanently archived
in the Concise Guide to PHARMACOLOGY 2019/20 (Alexander,
Christopoulos et al., 2019; Alexander, Fabbro, et al., 2019a, b).
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